Literature DB >> 19835429

HIV/AIDS epidemic in India and predicting the impact of the national response: mathematical modeling and analysis.

Arni S R Srinivasa Rao1, Kurien Thomas, Kurapati Sudhakar, Philip K Maini.   

Abstract

After two phases of AIDS control activities in India, the third phase of the National AIDS Control Programme (NACP III) was launched in July 2007. Our focus here is to predict the number of people living with HIV/AIDS (PLHA) in India so that the results can assist the NACP III planning team to determine appropriate targets to be activated during the project period (2007-2012). We have constructed a dynamical model that captures the mixing patterns between susceptibles and infectives in both low-risk and high-risk groups in the population. Our aim is to project the HIV estimates by taking into account general interventions for susceptibles and additional interventions, such as targeted interventions among high risk groups, provision of anti-retroviral therapy, and behavior change among HIV-positive individuals. Continuing the current level of interventions in NACP II, the model estimates there will be 5.06 million PLHA by the end of 2011. If 50 percent of the targets in NACP III are achieved by the end of the above period then about 0.8 million new infections will be averted in that year. The current status of the epidemic appears to be less severe compared to the trend observed in the late 1990s. The projections based on the second phase and the third phase of the NACP indicate prevention programmes which are directed towards the general and high-risk populations, and HIV-positive individuals will determine the decline or stabilization of the epidemic. Model based results are derived separately for the revised HIV estimates released in 2007. According to revised projections there will be 2.08 million PLHA by 2012 if 50 percent of the targets in NACP III are reached. We perform a Monte Carlo procedure for sensitivity analysis of parameters and model validation. We also predict a positive role of implementation of anti-retroviral therapy treatment of 90 percent of the eligible people in the country. We present methods for obtaining disease progression parameters using convolution approaches. We also extend our models to age-structured populations.

Entities:  

Mesh:

Year:  2009        PMID: 19835429     DOI: 10.3934/mbe.2009.6.779

Source DB:  PubMed          Journal:  Math Biosci Eng        ISSN: 1547-1063            Impact factor:   2.080


  4 in total

1.  Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the Estimation and Projection Package.

Authors:  Tarun Bhatnagar; Tapati Dutta; John Stover; Sheela Godbole; Damodar Sahu; Kangusamy Boopathi; Shilpa Bembalkar; Kh Jitenkumar Singh; Rajat Goyal; Arvind Pandey; Sanjay M Mehendale
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

2.  Epidemiological Characteristics and Transmissibility of Human Immunodeficiency Virus in Nanning City, China, 2001-2020.

Authors:  Qian Lin; Bin Deng; Jia Rui; Song-Bai Guo; Qingqing Hu; Qiuping Chen; Chi Tang; Lina Zhou; Zeyu Zhao; Shengnan Lin; Yuanzhao Zhu; Meng Yang; Yao Wang; Jingwen Xu; Xingchun Liu; Tianlong Yang; Peihua Li; Zhuoyang Li; Li Luo; Weikang Liu; Chan Liu; Jiefeng Huang; Min Yao; Mengni Nong; Liping Nong; Jinglan Wu; Na Luo; Shihai Chen; Roger Frutos; Shixiong Yang; Qun Li; Jing-An Cui; Tianmu Chen
Journal:  Front Public Health       Date:  2021-12-14

Review 3.  Impact of high-risk sex and focused interventions in heterosexual HIV epidemics: a systematic review of mathematical models.

Authors:  Sharmistha Mishra; Richard Steen; Antonio Gerbase; Ying-Ru Lo; Marie-Claude Boily
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

4.  Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers.

Authors:  Hannah Fraser; Annick Borquez; Jack Stone; Daniela Abramovitz; Kimberly C Brouwer; David Goodman-Meza; Matthew Hickman; Thomas L Patterson; Jay Silverman; Laramie Smith; Steffanie A Strathdee; Natasha K Martin; Peter Vickerman
Journal:  AIDS Behav       Date:  2021-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.